Sudeep Pharma Limited has formally notified stock exchanges about the resignation of John Garcia, Vice President of Sales & Supply Chain at its wholly owned subsidiary Sudeep Pharma USA Inc, effective February 6, 2026.

Regulatory Compliance Filing

The company submitted the mandatory disclosure to both National Stock Exchange of India Limited (NSE) and BSE Limited on February 5, 2026, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Company Secretary & Compliance Officer Dimple Mehta.

Official Documentation

According to the formal resignation letter submitted to the company, Garcia tendered his resignation on February 4, 2026, with his last working day scheduled for Friday, February 6, 2026. In his resignation letter addressed to Sendhil Pani, Garcia expressed gratitude for the opportunities provided and committed to ensuring a smooth transition during his final weeks.

Regulatory Disclosure Requirements

The company's filing includes comprehensive annexures as mandated by SEBI regulations. The disclosure confirms that Garcia is resigning to pursue new challenges and opportunities outside the organization. As a Senior Management Personnel (SMP) of the wholly owned subsidiary, his resignation requires formal notification to stock exchanges under the listing regulations.

Transition Planning

Garcia's departure affects critical business functions within the US subsidiary, particularly sales operations and supply chain management. In his resignation letter, he emphasized his commitment to completing outstanding tasks and facilitating the handover of responsibilities to the remaining team members during the transition period.

Sudeep Pharma Limited has disclosed that its wholly owned subsidiary has completed a significant land acquisition in Gujarat to establish a new manufacturing facility. The transaction, valued at ₹20.97 crores, represents a strategic expansion into battery-grade materials production.

Land Acquisition Details

Sudeep Advanced Materials Private Limited has purchased leasehold rights to land in Dahej, Gujarat from DCM Shriram Fine Chemicals Limited. The acquisition involves a substantial industrial plot within the Gujarat Industrial Development Corporation (GIDC) industrial estate.

Manufacturing Facility Purpose

The acquired land will be utilized to establish a commercial manufacturing facility focused on battery-grade precursor materials. The primary product to be manufactured at this facility will be iron phosphate, which is a crucial component in battery technology. This expansion indicates the company's strategic entry into the growing battery materials sector.

Transaction Structure

The land purchase involves leasehold rights rather than outright ownership, which is common for industrial plots within GIDC estates. The transaction consideration of ₹20.97 crores excludes transfer charges and other applicable duties that may be incurred during the completion process.

Regulatory Compliance

The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transaction completion remains subject to obtaining necessary approvals, consents, and permissions from concerned authorities. The company has confirmed that this transaction does not constitute a related party transaction and involves no connections with promoter groups.

Strategic Implications

This land acquisition represents Sudeep Pharma's diversification strategy through its subsidiary into the battery materials manufacturing sector. The focus on iron phosphate production aligns with the growing demand for battery-grade materials in various industrial applications. The Dahej location provides strategic advantages due to its established industrial infrastructure and connectivity within the GIDC framework.